Table 2.
Cognitive test scores at baseline (Session 1) and end of the double-blind phase (Session 2, Week 13).
| MEMANTINE | PLACEBO | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEST | BASELINE MEAN (SD) | END OF DOUBLE-BLIND MEAN (SD) | MEAN CHANGE (SD) | BASELINE MEDIAN (IQR) | END OF DOUBLE-BLIND MEDIAN (IQR) | MEDIAN CHANGE (IQR) | BASELINE MEAN (SD) | END OF DOUBLE-BLIND MEAN (SD) | MEAN CHANGE (SD) | BASELINE MEDIAN (IQR) | END OF DOUBLE-BLIND MEDIAN (IQR) | MEDIAN CHANGE (IQR) |
| 7–24 Spatial Recall Testn | ||||||||||||
| Learning | 31.86 (3.34) | 32.86 (2.55) | 1.00 (2.00) | 34.00 (7.00) | 33.00 (3.00) | −1.00 (3.00) | 27.44 (5.46) | 29.22 (3.56) | 1.78 (4.99) | 28.00 (10.00) | 30.00 (5.00) | 1.00 (8.00) |
| Immediate Recall | 6.29 (1.50) | 6.43 (0.79) | 0.14 (1.77) | 7.00 (1.00) | 7.00 (1.00) | 0.00 (1.00) | 6.00 (1.58) | 6.11 (1.36) | 0.11 (1.45) | 6.00 (1.00) | 7.00 (3.00) | 0.00 (2.00) |
| Delayed Recall | 5.71 (1.60) | 6.29 (1.25) | 0.57 (1.62) | 6.00 (3.00) | 7.00 (2.00) | 0.00 (1.00) | 5.56 (1.74) | 6.22 (0.83) | 0.67 (1.41) | 6.00 (3.00) | 6.00 (2.00) | 0.00 (1.00) |
| Selective Reminding Test | ||||||||||||
| LTSa | 40.63 (9.81) | 47.63 (12.13) | 7.00 (7.86) | 40.50 (19.00) | 52.00 (13.00) | 9.00 (13.00) | 37.11 (17.48) | 44.56 (14.44) | 7.44 (12.11) | 35.00 (28.00) | 47.00 (26.00) | 9.00 (14.00) |
| CLTRb | 32.75 (10.33) | 37.13 (12.90) | 4.38 (7.60) | 35.50 (21.00) | 39.00 (10.00) | 6.00 (13.00) | 24.67 (12.55) | 32.78 (14.47) | 8.11 (9.51) | 21.00 (17.00) | 29.00 (24.00) | 7.00 (16.00) |
| Delayed Recall | 6.25 (3.77) | 6.75 (4.10) | 0.50 (3.25) | 8.00 (7.00) | 8.00 (7.00) | 1.00 (5.00) | 5.67 (3.91) | 6.56 (4.04) | 0.89 (3.98) | 6.00 (7.00) | 6.00 (8.00) | 1.00 (3.00) |
| Digit Span | 18.50 (3.67) | 19.25 (3.99) | 0.75 (3.62) | 18.50 (6.00) | 20.50 (6.00) | 0.50 (6.00) | 19.33 (5.75) | 19.00 (4.27) | −0.33 (4.15) | 19.00 (11.00) | 18.00 (7.00) | −1.00 (8.00) |
| Spatial Spanc | 16.25 (4.20) | 17.13 (3.98) | 0.88 (2.23) | 16.50 (7.00) | 16.50 (6.00) | 2.00 (2.00) | 14.67 (1.50) | 17.11 (2.37) | 2.44 (2.88) | 15.00 (2.00) | 17.00 (4.00) | 3.00 (6.00) |
| Block Designn | 59.57 (4.28) | 61.43 (5.74) | 1.86 (3.93) | 59.00 (6.00) | 60.50 (13.00) | 0.00 (3.00) | 54.22 (7.98) | 57.22 (5.91) | 3.00 (5.20) | 55.00 (13.00) | 56.00 (9.00) | 2.00 (7.00) |
| Stroop Color Word Interference Test | 119.78 (29.33) | 110.82 (27.74) | −8.97 (10.67) | 112.19 (20.61) | 99.17 (23.80) | −8.88 (16.15) | 120.93 (29.34) | 110.36 (26.21) | −10.57 (24.66) | 126.00 (42.80) | 109.00 (45.44) | −6.00 (11.16) |
| DKEFS Verbal Fluency | 96.00 (21.59) | 96.63 (13.75) | 0.63 (12.01) | 100.00 (41.00) | 98.00 (19.00) | −2.00 (15.00) | 96.44 (27.25) | 101.11 (23.68) | 4.67 (11.73) | 86.00 (39.00) | 98.00 (43.00) | 3.00 (15.00) |
| DKEFS Design Fluency | 30.38 (9.67) | 36.50 (6.99) | 6.13 (7.74) | 32.00 (16.00) | 36.50 (13.00) | 8.50 (13.00) | 30.11 (4.91) | 33.78 (3.15) | 3.67 (6.71) | 31.00 (9.00) | 34.00 (4.00) | 1.00 (13.00) |
| QOLIE Memory | 43.43 (14.21) | 52.15 (20.83) | 8.72 (20.07) | 45.14 (25.56) | 64.03 (39.86) | 7.92 (37.51) | 34.60 (23.78) | 45.25 (25.87) | 10.65 (14.34) | 26.67 (38.48) | 34.17 (43.07) | 10.00 (24.72) |
LTS = long-term storage; CLTR = continuous long-term retrieval; DKEFS = Delis–Kaplan Executive Functioning System; QOLIE = quality of life in epilepsy inventory. The table contains raw scores, with the CLTR and LTS scores including standard adjustments for age and sex.
Differences in baseline performance and change scores compared across memantine and placebo groups did not reach statistical significance.
Data were excluded from 3 subjects because of seizures during/within 3 days of testing. Hence, data were based on n = 8 memantine group and n = 9 placebo group.
Due to isolated missing measures (1 subject), n = 7 memantine and n = 9 placebo.
Marginally significant improvement in posttreatment/placebo (Session 2) compared with baseline (Session 1) performance at p = 0.05 in the memantine group.
Significant improvement in posttreatment/placebo (Session 2) compared with baseline (Session 1) performance at p = 0.033 in the placebo group.
Significant improvement in posttreatment/placebo (Session 2) compared with baseline (Session 1) performance at p = 0.042 in the placebo group. Such results are likely due to practice effects and should be interpreted with caution.